Author Archive: Jeremy Parkinson

Our Highest-Conviction Fixed Income Trade Over The Next 2 Years

Our Highest-Conviction Fixed Income Trade Over The Next 2 Years

On March 21, the Federal Open Market Committee voted to increase the Federal Funds Rate target for the sixth time since December 2015. As the Federal Reserve (Fed) continues to tighten policy, the ability to generate returns in short-dated fixed income has increased. In response, investors have piled nearly $6.7 billion over the last year into two exchange-traded funds (ETFs) that […]
Gold’s Old Friend Comes Back

Gold’s Old Friend Comes Back

Remember LIBOR? The interest rate which soared during the global financial crisis? It’s on the rise again, but almost no one is paying adequate attention to it. We are – and we will analyze for you what this means for the gold market. Hello LIBOR, My Old Friend Simon and Garfunkel sang about darkness, the […]
Scrooge’s Income ‘L’

Scrooge’s Income ‘L’

We keep revisiting the concept of “residual seasonality” quite purposefully, even though on its face it is an absurd one. It is in every way emblematic of the current state of Economics and the commentary derived from it. Residual seasonality is the kind of delusion that has become commonplace, a coping mechanism for an economy […]
Amazon Stock: What Might Donald Trump Actually Be Able To Do?

Amazon Stock: What Might Donald Trump Actually Be Able To Do?

Amazon.com, Inc. (Nasdaq: AMZN) stock settled in for a second consecutive day of declines on Thursday following President Trump’s latest tweet about the online retailer. It seemed to confirm what we heard earlier this week, which was that the president was said to be “obsessed” with Amazon. However, analysts have been quick to try to calm […]
EUR/USD, GBP/USD Test Support; USD Jumps To 90.00 As Quarter-End Nears

EUR/USD, GBP/USD Test Support; USD Jumps To 90.00 As Quarter-End Nears

DOLLAR BULLS SHOW UP AS END OF Q1 NEARS While equities were on the move earlier in the week with currencies taking a back seat to the action, the roles reversed yesterday as the US Dollar shot-higher while the S&P 500 meandered within a range. The big item over the past 24 hours was a jump of USD strength as DXY rallied back-above […]
April Seasonality For Commodities ETF

April Seasonality For Commodities ETF

Our amazing new Stock Seasonality Tool lets users track seasonality trends for any stock, ETF, index, or asset class over any time period throughout the year.With the month of April starting up next week, we wanted to show how the various commodities ETFs have historically performed during the month. The chart below is a direct snapshot from […]
What’s Really Driving Expedia Inc’s Declining ROE?

What’s Really Driving Expedia Inc’s Declining ROE?

Expedia Inc. (Nasdaq: EXPE) delivered a below average 6.4% ROE over the past year, compared to the 8.8% return generated by the Consumer Discretionary sector. Expedia’s results may indicate management is running an inefficient business relative to its peers, which may very well be the case, but it is important to understand what ROE is made […]
Techlash Crushes Cryptos – Bitcoin Tumbles 50% In Q1, Back Below $8k

Techlash Crushes Cryptos – Bitcoin Tumbles 50% In Q1, Back Below $8k

Bitcoin has tumbled overnight, back below $8,000, and is now down 48% year-to-date, as cryptocurrencies have accelerated lower this week amid the carnage in tech stocks. Bitcoin’s dead-cat-bounce did not last long… But the week has been a bloodbath for all cryptocurrencies… And the overnight weakness is most interesting considering the PBOC appeared to ease back away […]
Protagonist Therapeutics, Inc. Shares Fell 54% Yesterday After Abandoning Phase 2 Trial Of Lead Drug

Protagonist Therapeutics, Inc. Shares Fell 54% Yesterday After Abandoning Phase 2 Trial Of Lead Drug

Shares of Protagonist Therapeutics (PTGX) dropped 54% in after-hours trading on Tuesday after announcing it would discontinue phase 2b Propel trial. The pharmaceutical company was conducting a research on a compound called PTG-100 to see if it was a potential treatment for ulcerative colitis. The company’s decision to bring the study to an early halt […]
Constellation Brands (STZ) Tops Q4 Earnings, Guides For FY19

Constellation Brands (STZ) Tops Q4 Earnings, Guides For FY19

Constellation Brands Inc. (STZ – Free Report) delivered robust fourth-quarter fiscal 2018 results, wherein both the top and bottom line topped estimates and improved year over year. Notably, this marked the 14th consecutive quarter of earnings beat for the company. Further, it provided an upbeat outlook for fiscal 2019. Consequently, shares of Constellation Brands rose nearly 3.1% in […]